drugset
drugset / Trial / NCT05604170

Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy

NCT05604170 ↗

Phase 3 Terminated 117 enrolled Marinus Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated in either Study 1042-TSC-3001 or Study 1042-TSC-2001

Timeline

Start
2022-05-16
Primary completion
2025-04-02
Completion
2025-04-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganaxolone Small molecule — Oral

Indications

tuberous sclerosis